CDK
Os inibidores das quinases dependentes de ciclinas (CDK) são compostos que bloqueiam a atividade das CDKs, um grupo de quinases de proteínas que regulam o ciclo celular, a transcrição e outros processos celulares. As CDKs são ativadas pela ligação às ciclinas, e sua atividade é crucial para a progressão das células através das diferentes fases do ciclo celular. Inibir as CDKs pode interromper a divisão celular, levando à parada do ciclo celular e à apoptose, especialmente em células cancerígenas onde as CDKs frequentemente estão desreguladas. Os inibidores de CDK são amplamente utilizados na pesquisa do câncer e têm potencial terapêutico no tratamento de vários tipos de câncer. Na CymitQuimica, oferecemos uma seleção abrangente de inibidores de CDK de alta qualidade para apoiar sua pesquisa em controle do ciclo celular, câncer e desenvolvimento terapêutico.
Foram encontrados 500 produtos de "CDK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Cdc7-IN-1
CAS:<p>Cdc7-IN-1: selective ATP-competitive Cdc7 kinase inhibitor; IC50 0.6 nM at 1mM ATP; induces cancer cell death.</p>Fórmula:C21H16ClN3O4Cor e Forma:SolidPeso molecular:409.82CDK9-IN-14
CAS:<p>CDK9-IN-14: Potent CDK9 inhibitor, IC50=6.92 nM, effective on MV-4-11 cells and in vivo tumors, low toxicity, minimal side effects.</p>Fórmula:C21H23F2N3O4Cor e Forma:SolidPeso molecular:419.42CLK1/2-IN-3
CAS:<p>CLK1/2-IN-3 (Cpd-3) is a CLK1 and CLK2 inhibitor with antiproliferative activity that inhibits the activity of CLK and SRPK.</p>Fórmula:C21H21N5O2Pureza:99.04%Cor e Forma:SolidPeso molecular:375.42THZ1-R
CAS:<p>THZ1-R is a non-covalent active analogue of THZ1, with the acrylamide group removed from THZ1, not covalently bind to the C312 cysteine residue of CDK7.</p>Fórmula:C31H30ClN7O2Pureza:98%Cor e Forma:SolidPeso molecular:568.07CLK1-IN-1
CAS:<p>CLK1-IN-1 is a potent and selective inhibitor of the Cdc2-like kinase 1 (CLK1; IC50: 2 nM).</p>Fórmula:C24H16FN5OCor e Forma:SolidPeso molecular:409.42CDK12-IN-E9
CAS:<p>CDK12-IN-E9 is a potent and selective covalent CDK12 inhibitor and non-covalent CDK9 inhibitor while avoiding ABC transporter-mediated efflux.</p>Fórmula:C24H30N6O2Cor e Forma:SolidPeso molecular:434.53Cdc7-IN-17
CAS:<p>Cdc7-IN-17 is a potent inhibitor of CDC7 with an IC 50 of <10 μM that can be used in cancer research [1].</p>Fórmula:C13H15N5OSCor e Forma:SolidPeso molecular:289.36AS2863619 free base
CAS:<p>AS2863619 free base enables the conversion of antigen-specific effector/memory T cells into Foxp3+ regulatory T (Treg) cells.</p>Fórmula:C16H12N8OCor e Forma:SolidPeso molecular:332.32Cdc7-IN-4
CAS:<p>Cdc7-IN-4 is a potent inhibitor of Cdc7 kinase.</p>Fórmula:C22H24F3N5O4Pureza:98%Cor e Forma:SolidPeso molecular:479.45K 00546
CAS:<p>K00546 inhibits CDK1/cyclin B (IC50: 0.6 nM), CDK2/cyclin A (IC50: 0.5 nM), CLK1 (IC50: 8.9 nM), and CLK3 (IC50: 29.2 nM).</p>Fórmula:C15H13F2N7O2S2Pureza:99.12%Cor e Forma:SolidPeso molecular:425.44CDK8-IN-7
CAS:<p>CDK8-IN-7 is a potent CDK8 inhibitor with a Kd of 3.5 nM, showing promise for AML research.</p>Fórmula:C30H40N2Cor e Forma:SolidPeso molecular:428.65Cdc7-IN-15
CAS:<p>Cdc7-IN-15 (Example 108) is an inhibitor of cdc7 kinase that has potential to be used for cancer research [1].</p>Fórmula:C12H14N4OSCor e Forma:SolidPeso molecular:262.33CP681301
CAS:<p>CP681301 is a potent CDK5 inhibitor with anti-tumor effects in Drosophila and reduces Glioma stem cells' growth and renewal.</p>Fórmula:C17H22N4OCor e Forma:SolidPeso molecular:298.38MDK6204
CAS:<p>MDK6204 is a selective inhibitor of CLK1 and CLK2.</p>Fórmula:C20H20N6OPureza:98%Cor e Forma:SolidPeso molecular:360.41BSJ-01-175
CAS:<p>BSJ-01-175: Selective, potent covalent inhibitor of CDK12/13, targets cancer cells, inhibits phosphorylated RNA polymerase II, downregulates CDK12 genes.</p>Fórmula:C30H33ClN6O2Cor e Forma:SolidPeso molecular:545.08Indirubin-3'-monoxime-5-sulphonic acid
CAS:<p>Indirubin-3'-monoxime-5-sulphonic acid is a potent and selective inhibitor of GSK-3β, CDK5, and CDK1 with IC50s of 80nM,5 nM, and 7 nM, respectively.</p>Fórmula:C16H11N3O5SPureza:98%Cor e Forma:SolidPeso molecular:357.34CDK7-IN-13
CAS:<p>CDK7-IN-13: A potent pyrimidine-based CDK7 inhibitor, potential for various cancers. See CN114249712A.</p>Fórmula:C20H23F3N6OSPureza:99.22%Cor e Forma:SolidPeso molecular:452.5P18IN003
CAS:<p>P18IN003 is a selective and effective p18(INK4C) inhibitor that inhibits the activity of p18 protein and can be used to study in vitro expansion of</p>Fórmula:C17H16N2O3Pureza:98.77%Cor e Forma:SolidPeso molecular:296.32CDK7-IN-20
<p>CDK7-IN-20: potent, irreversible CDK7 inhibitor, IC50 of 4nM, 206x selectivity vs. other CDKs, potential for ADPKD study.</p>Fórmula:C30H26N6O3Cor e Forma:SolidPeso molecular:518.57FLT3/CDK4-IN-1
CAS:<p>FLT3/CDK4-IN-1: Oral FLT3 (7 nM IC50) & CDK4 (11 nM IC50) inhibitor with strong in vivo anti-cancer properties.</p>Fórmula:C25H28F2N8Cor e Forma:SolidPeso molecular:478.54BS-181
CAS:<p>BS-181 is a highly selective CDK7 inhibitor (IC50: 21 nM); >40-fold selective for CDK7 than CDK1/2/4/5/6/9.</p>Fórmula:C22H32N6Pureza:98%Cor e Forma:SolidPeso molecular:380.53CDK4/6-IN-12
CAS:<p>CDK4/6-IN-12 inhibits CDK4/6 with IC50s of 592.3 nM & 3090 nM, useful in cancer research.</p>Fórmula:C12H10N6Cor e Forma:SolidPeso molecular:238.25CGP60474
CAS:<p>CGP60474 is an inhibitor of VEGFR-2 (IC50 = 84 nM) and an inhibitor of ATP-competitive PKC.</p>Fórmula:C18H18ClN5OPureza:98.81%Cor e Forma:SolidPeso molecular:355.82CCT068127
CAS:<p>CCT068127 is a potent CDK2 and CDK9 inhibitor.</p>Fórmula:C19H27N7OCor e Forma:SolidPeso molecular:369.46(S)-CR8
CAS:<p>(S)-CR8 is an effective second-generation cyclin-dependent kinase inhibitor.</p>Fórmula:C24H29N7OCor e Forma:SolidPeso molecular:431.53CDK7-IN-8
CAS:<p>CDK7-IN-8 is a potent inhibitor of CDK7 (IC50: 54.29 nM) and exhibits inhibitory activity against several cancer cells and in vivo tumor models.</p>Fórmula:C25H38N8O3Cor e Forma:SolidPeso molecular:498.62EGFR/HER2/CDK9-IN-3
CAS:<p>EGFR/HER2/CDK9-IN-3 inhibits EGFR (191.08 nM IC50), HER2 (132.65 nM), CDK9 (113.98 nM); shows anti-tumor effects.</p>Fórmula:C24H21N3O4S2Cor e Forma:SolidPeso molecular:479.57Aloisine A
CAS:<p>Aloisine A, a CDK/GSK-3 inhibitor with IC50: Cdk1/B-150nM, Cdk2/A-120nM, Cdk2/E-400nM, Cdk5/25-200nM, Cdk5/35-160nM, GSK-3α-500nM, GSK-3β-650nM, JNK-3-10μM.</p>Fórmula:C16H17N3OPureza:98%Cor e Forma:SolidPeso molecular:267.33TP1287
CAS:<p>TP-1287 is an oral phosphate prodrug of the CDK9 inhibitor, alvocidib.</p>Fórmula:C21H21ClNO8PCor e Forma:SolidPeso molecular:481.82Indirubin-5-sulfonate
CAS:<p>Indirubin-5-sulfonate inhibits GSK-3β & CDKs with IC50: 55/35/150/300/65 nM for CDK1/B, 2/A&E, 4/D1, 5/p35.</p>Fórmula:C16H10N2O5SPureza:98%Cor e Forma:SolidPeso molecular:342.33Crozbaciclib fumarate
CAS:<p>Crozbaciclib fumarate is a CDK4/6 inhibitor with IC 50 s of 3 and 1 nM, respectively.</p>Fórmula:C32H34F2N6O4Cor e Forma:SolidPeso molecular:604.65CDK7-IN-12
CAS:<p>CDK7-IN-12 inhibits CDK7 to control transcription and cell cycle, halting tumor growth in vitro/vivo with cancer research potential.</p>Fórmula:C20H19F3N6Cor e Forma:SolidPeso molecular:400.4CDK1-IN-1
CAS:<p>CDK1-IN-7 inhibits CDK1 at 161.2 nM, triggers p53-dependent apoptosis, and selectively targets tumor growth.</p>Fórmula:C27H23N5O3Cor e Forma:SolidPeso molecular:465.5CDK4/6-IN-9
CAS:<p>CDK4/6-IN-9 selectively inhibits CDK4/6 (IC50: 905 nM); potential for MM research.</p>Fórmula:C22H23FN8Cor e Forma:SolidPeso molecular:418.47Cdc7-IN-13
CAS:<p>Cdc7-IN-13 (compound 84) is a highly potent CDC7 inhibitor, exhibiting an IC50 value of <1 nM. This compound holds promise for cancer research [1].</p>Fórmula:C18H20N4O2SCor e Forma:SolidPeso molecular:356.44Ulecaciclib
CAS:<p>Ulecaciclib: oral, BBB-permeable CDK inhibitor; favorable pharmacokinetics; ki: 0.62 μM (CDK2/A), 3 nM (CDK6/D3), 0.2 nM (CDK4/D1), 0.63 μM (CDK7/H).</p>Fórmula:C25H33FN8SCor e Forma:SolidPeso molecular:496.65FN-1501
CAS:<p>FN-1501 is a potent FLT3 and CDK inhibitor (IC50s: 2.47, 0.85, 1.96, and 0.28 nM for CDK2/cyclin A, CDK4/cyclin D1, CDK6/cyclin D1 and FLT3, respectively).</p>Fórmula:C22H25N9OPureza:97.4%Cor e Forma:SolidPeso molecular:431.49JTK-101
CAS:<p>JTK-101 is a potent and selective Tat-dependent HIV-1 replication inhibitor.</p>Fórmula:C25H23N3O3Cor e Forma:SolidPeso molecular:413.47(E/Z)-BIO-acetoxime
CAS:<p>(E/Z)-BIO-acetoxime: potent GSK-3 α/β inhibitor; IC50: GSK-3α/β 10nM, CDK5/p25 2.4μM, CDK2/A 4.3μM, CDK1/B 63μM.</p>Fórmula:C18H12BrN3O3Cor e Forma:SolidPeso molecular:398.21(S)-LY3177833 hydrate
CAS:<p>(S)-LY3177833 ((S)-Example 2) hydrate, an orally active CDC7 kinase inhibitor, exhibits extensive in vitro anticancer efficacy.</p>Fórmula:C16H14FN5O2Cor e Forma:SolidPeso molecular:327.31RP-106
CAS:<p>RP-106 is an ATP-competitive inhibitor of CDK5/p25, CDK1/cyclin B, and GSK-3.</p>Fórmula:C17H19N3OPureza:98%Cor e Forma:SolidPeso molecular:281.35PKC-9
CAS:<p>PKC-9 is a PKC-zeta inhibitor 9.</p>Fórmula:C25H25N7Cor e Forma:SolidPeso molecular:423.51CDK4/6-IN-7
CAS:<p>CDK4/6-IN-7 is an oral, potent CDK4/6 inhibitor with IC50s of 1.58/4.09 nM, crucial for breast cancer studies.</p>Fórmula:C18H18ClN5O3Cor e Forma:SolidPeso molecular:387.82Cdc7-IN-3
CAS:<p>Cdc7-IN-3 is a potent inhibitor of Cdc7 kinase.</p>Fórmula:C20H22N4O5Pureza:98%Cor e Forma:SolidPeso molecular:398.41CDK7-IN-2
CAS:<p>CDK7-IN-2 inhibits CDK7, essential for RNA polymerase II activation and cell cycle control, with cancer research potential.</p>Fórmula:C26H39N7O3Cor e Forma:SolidPeso molecular:497.63EGFR/HER2/CDK9-IN-1
CAS:<p>EGFR/HER2/CDK9-IN-1 is a potent inhibitor (IC50: EGFR 90.17 nM, HER2 131.39 nM, CDK9 67.04 nM) with notable anti-tumor activity.</p>Fórmula:C23H21N3O3S2Cor e Forma:SolidPeso molecular:451.56CDK5 inhibitor 20-223
CAS:<p>CDK5 inhibitor 20-223 is a potent CDK2/CDK5 inhibitor,anti-Colorectal Cancer (CRC), inhibiting cell migration and inducing cell cycle arrest.</p>Fórmula:C19H19N3OCor e Forma:SolidPeso molecular:305.37FN-1501-propionic acid
CAS:<p>FN-1501-propionic acid, a CDK2/9 ligand, in conjunction with a CRBN ligand, has been utilized in the design of a PROTAC CDK2/9 degrader.</p>Fórmula:C25H27N9O4Pureza:98%Cor e Forma:SolidPeso molecular:517.54EGFR/HER2/CDK9-IN-2
CAS:<p>EGFR/HER2/CDK9-IN-2 inhibits EGFR, HER2, CDK9 with IC50s: 145.35, 129.07, 117.13 nM; strong antitumor effects.</p>Fórmula:C23H20N4O5S2Cor e Forma:SolidPeso molecular:496.56CDK8-IN-10
CAS:<p>CDK8-IN-10 is a selective and potent inhibitor of cell cycle protein-dependent kinase (CDK8) (IC50: 8.25 nM) that can be used to study cancer.</p>Fórmula:C25H15ClF3N5O3Cor e Forma:SolidPeso molecular:525.87
